CA3155187A1 - Compositions et procedes associes a des constructions de domaine de liaison a l'antigene fc diriges sur cd38 - Google Patents

Compositions et procedes associes a des constructions de domaine de liaison a l'antigene fc diriges sur cd38 Download PDF

Info

Publication number
CA3155187A1
CA3155187A1 CA3155187A CA3155187A CA3155187A1 CA 3155187 A1 CA3155187 A1 CA 3155187A1 CA 3155187 A CA3155187 A CA 3155187A CA 3155187 A CA3155187 A CA 3155187A CA 3155187 A1 CA3155187 A1 CA 3155187A1
Authority
CA
Canada
Prior art keywords
domain
monomer
polypeptide
amino acid
domain monomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3155187A
Other languages
English (en)
Inventor
Daniel ORTIZ
Amit Choudhury
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Choudhury Amit
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Choudhury Amit, Momenta Pharmaceuticals Inc filed Critical Choudhury Amit
Publication of CA3155187A1 publication Critical patent/CA3155187A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des constructions de liaison à l'antigène Fc ayant un domaine de liaison à CD38 et au moins deux domaines Fc, ainsi que des procédés d'utilisation de telles constructions. L'invention concerne également des polypeptides constituant de telles constructions. Les monomères de domaine Fc qui sont inclus dans les constructions peuvent comprendre des substitutions d'acides aminés qui favorisent l'homodimérisation ou l'hétérodimérisation.
CA3155187A 2019-09-18 2020-09-18 Compositions et procedes associes a des constructions de domaine de liaison a l'antigene fc diriges sur cd38 Pending CA3155187A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902380P 2019-09-18 2019-09-18
US62/902,380 2019-09-18
PCT/US2020/051663 WO2021055876A1 (fr) 2019-09-18 2020-09-18 Compositions et procédés associés à des constructions de domaine de liaison à l'antigène fc dirigés sur cd38

Publications (1)

Publication Number Publication Date
CA3155187A1 true CA3155187A1 (fr) 2021-03-25

Family

ID=74884204

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3155187A Pending CA3155187A1 (fr) 2019-09-18 2020-09-18 Compositions et procedes associes a des constructions de domaine de liaison a l'antigene fc diriges sur cd38

Country Status (10)

Country Link
EP (1) EP4031166A1 (fr)
JP (1) JP2022548925A (fr)
KR (1) KR20220119362A (fr)
CN (1) CN114786713A (fr)
AU (1) AU2020351234A1 (fr)
BR (1) BR112022005036A2 (fr)
CA (1) CA3155187A1 (fr)
IL (1) IL291465A (fr)
MX (1) MX2022003316A (fr)
WO (1) WO2021055876A1 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1945671A2 (fr) * 2005-10-12 2008-07-23 MorphoSys AG Generation et profilage d'anticorps therapeutiques derives de hucal gold entierement humains, specifiques de cd38 humain
JP5913980B2 (ja) * 2008-10-14 2016-05-11 ジェネンテック， インコーポレイテッド 免疫グロブリン変異体及びその用途
JP6673838B2 (ja) * 2014-02-14 2020-04-01 セレクティスＣｅｌｌｅｃｔｉｓ 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞
WO2015197582A1 (fr) * 2014-06-27 2015-12-30 Innate Pharma Protéines monomères multispécifiques de liaison aux antigènes
RU2019124709A (ru) * 2017-01-06 2021-02-08 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА

Also Published As

Publication number Publication date
IL291465A (en) 2022-05-01
WO2021055876A1 (fr) 2021-03-25
CN114786713A (zh) 2022-07-22
MX2022003316A (es) 2022-07-11
KR20220119362A (ko) 2022-08-29
EP4031166A1 (fr) 2022-07-27
BR112022005036A2 (pt) 2022-07-05
AU2020351234A1 (en) 2022-04-28
JP2022548925A (ja) 2022-11-22

Similar Documents

Publication Publication Date Title
US20200040084A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
US20210317227A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
US20220267460A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
US20210147549A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
CA3105985A1 (fr) Compositions et methodes associees a des constructions de domaine de liaison a un antigene fc ciblees sur ccr4
CA3155187A1 (fr) Compositions et procedes associes a des constructions de domaine de liaison a l'antigene fc diriges sur cd38
AU2019300020A1 (en) Compositions and methods related to engineered Fc-antigen binding domain constructs